Physician profile
Todd A Bush
NPI 1689624595
$632.21
in general payments reported to CMS, 2019-2025
16 companies · $19.30 in 2025
The $19.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $11.01 · 2021: $37.87 · 2022: $146 · 2023: $95.83 · 2024: $58.11 · 2025: $19.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $111.01 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $99.54 | 2021-2025 | Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $71.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $51.33 | 2019-2022 | |
| Lilly USA, LLC | $50.58 | 2019-2024 | Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $31.49 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.71 | 2022 | |
| Amarin Pharma, INC. | $30.67 | 2019 | |
| Amgen INC. | $29.89 | 2019 | |
| Glaxosmithkline, LLC. | $26.88 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.86 | 2019 | |
| Pfizer INC. | $17.86 | 2023 | |
| Shield Therapeutics INC | $14.70 | 2023 | Accrufer |
| Astellas Pharma US INC | $14.18 | 2019 | |
| Dexcom, INC. | $13.58 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.